ResMed Inc. (RMD) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025 (Q1 of fiscal year 2026). ResMed Inc. is a global leader in medical devices and cloud-based software for diagnosing and treating sleep-disordered breathing and other respiratory disorders. The company operates two segments: Sleep and Breathing Health (devices and masks) and Residential Care Software (SaaS platforms).
Key Financial Metrics
| Metric | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Net Revenue | $1,335.6 million | $1,224.5 million |
| Gross Profit | $820.8 million | $717.2 million |
| Gross Margin | 61.5% | 58.6% |
| Operating Income | $446.5 million | $387.3 million |
| Net Income | $348.5 million | $311.4 million |
| Diluted EPS | $2.37 | $2.11 |
| Operating Cash Flow | $457.3 million | $325.5 million |
| Cash & Equivalents | $1,383.8 million | $426.4 million |
| Total Debt (Net) | $668.6 million | $668.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 9% year-over-year (8% on a constant currency basis). Sleep and Breathing Health revenue grew 10%, driven by increased unit sales of devices and masks in both the Americas and international markets. Residential Care Software revenue grew 6%.
- Margin Expansion: Gross margin improved by 290 basis points to 61.5%, attributed to manufacturing/logistics efficiencies and component cost improvements.
- Restructuring Costs: The company recorded $15.8 million in restructuring expenses related to employee severance and workforce planning, compared to none in the prior year.
- Interest Income: Net interest income turned positive ($8.8 million) from a net expense ($1.7 million) in the prior year due to lower debt levels following repayments on the revolving credit facility.
- Tax Rate: The effective tax rate increased to 22.0% from 18.8%, primarily due to global minimum taxes (Pillar Two) and a shift in the global mix of earnings.
Guidance, Outlook, and Risks
- Outlook: Management expects cash from operations to fluctuate based on supply chain conditions and working capital. The company maintains a strong liquidity position with $1.5 billion available under its revolving credit facility.
- Capital Allocation: The company repurchased $150.0 million of treasury stock (523,212 shares) during the quarter. A quarterly dividend of $0.60 per share was declared.
- Risks & Contingencies:
- Legal Proceedings: Ongoing patent litigation with New York University (NYU) and Cleveland Medical Devices. While the Federal Circuit affirmed the invalidation of NYU patents in August 2025, appeals regarding Cleveland Medical patents remain pending. A new suit was filed by Fractus, S.A. in October 2025 regarding antenna technology.
- Taxation: Continued evaluation of the impact of OECD Pillar Two global minimum tax rules.
- Market Risk: Significant exposure to foreign currency fluctuations (EUR, AUD, SGD), managed through hedging programs.
Investor Verification Checklist
- Verify the sustainability of the gross margin expansion (61.5%) given global supply chain and component cost pressures.
- Monitor the resolution of the Cleveland Medical patent litigation, specifically the pending appeals and PTAB reviews, as these could impact future product sales.
- Assess the impact of global minimum taxes (Pillar Two) on future effective tax rates and net income.
- Review the restructuring plan execution and the remaining accrual of $11.7 million to ensure no further material charges are anticipated.
- Confirm the trajectory of Residential Care Software growth, noting the offset between strong MEDIFOX DAN performance and weaker Senior Living verticals.